The use of imiquimod in the treatment of periocular tumours

Orbit

Volumn 29, Issue 2, 2010, Pages 83-87

  Ross, A H ^a   Kennedy, C T C ^b   Collins, C ^b   Harrad, R A ^a  

^a BRISTOL EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Imiquimod; Periocular tumours; Squamous cell carcinoma

Indexed keywords

IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; BASAL CELL CARCINOMA; BOWEN DISEASE; CASE STUDY; CLINICAL ARTICLE; CONJUNCTIVITIS; DEPIGMENTATION; DRUG DOSE REDUCTION; EYELID TUMOR; FEMALE; HUMAN; INTRAEPIDERMAL SQUAMOUS CELL CARCINOMA; MALE; RETROSPECTIVE STUDY; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR DIFFERENTIATION;

ADMINISTRATION, TOPICAL; AGED; AMINOQUINOLINES; ANTINEOPLASTIC AGENTS; BOWEN'S DISEASE; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; EYELID NEOPLASMS; FEMALE; HUMANS; KERATOSIS, ACTINIC; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; RETROSPECTIVE STUDIES; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 77951275514     PISSN: 01676830     EISSN: 17445108     Source Type: Journal    
DOI: 10.3109/01676830903294909     Document Type: Article

References (23)

1. Berman B, Sullivan T, De Araujo T, Nadji M. Expression of Fas-receptor on basal cell carcinomas after treatment with imiquimod 5% cream or vehicle. Br J Dermatol. 2003 Nov;149 Suppl 66:59-61. (Pubitemid 38064522)
2. Blasi MA, Giammaria D, Balestrazzi E. Immunotherapy with imiquimod 5% cream for eyelid nodular basal cell carcinoma. Am J Ophthalmol. 2005 Dec;140(6):1136-1139. (Pubitemid 41821311)
3. Brannan PA, Anderson HK, Kersten RC, Kulwin DR.Bowen disease of the eyelid successfully treated with imiquimod. Ophthal Plast Reconstr Surg. 2005 Jul;21(4):321-322. (Pubitemid 41099853)
4. Cataltepe S, Gornstein ER, Schick C, Kamachi Y, Chatson K, Fries J, Silverman GA, Upton MP. Co-expression of the squamous cell carcinoma antigens 1 and 2 in normal adult human tissues and squamous cell carcinomas. J Histochem Cytochem. 2000 Jan;48(1):113-122. (Pubitemid 30053572)
5. Choontanom R, Thanos S, Busse H, Stupp T. Treatment of basal cell carcinoma of the eyelids with 5% topical imiquimod: a 3-year follow-up study. Graefes Arch Clin Exp Ophthalmol. 2007 Aug; 245(8):1217-1220. (Pubitemid 47034345)
6. Flórez Á, Feal C, de la Torre C, Cruces M. Invasive squamous cell carcinoma treated with imiquimod 5% cream. Acta Derm Venereol. 2004;84:227-228. (Pubitemid 38649402)
7. Hengge UR, Benninghoff B, Ruzicka T, Goos M. Topical immunomodulators- progress towards treating inflammation, infection, and cancer. Lancet Infect Dis. 2001 Oct;1(3):189-198. (Pubitemid 33586052)
8. Hengge UR, Ruzicka T. Topical immunomodulation in dermatology: potential of toll-like receptor agonists. Dermatol Surg. 2004 Aug;30(8):1101-1112. Review. (Pubitemid 39120673)
9. Hengge UR, Schaller J. Successful treatment of invasive squamous cell carcinoma using topical imiquimod. Arch Dermatol. 2004 Apr; 140:404-406. (Pubitemid 38469242)
10. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, Lee JH, Fox TL. Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004 May; 50(5):714-721. (Pubitemid 38580548)
11. Leppälä J, Kaarniranta K, Uusitalo H, Kontkanen M. Imiquimod in the treatment of eyelid basal cell carcinoma. Acta Opthalmol Scand. 2007 Aug;85(5):566-568. Epub 2007 Mar 22. (Pubitemid 47163120)
12. Martin-Garcia RF. Imiquimod: an effective alternative for the treatment of invasive cutaneous squamous cell carcinoma. Dermatol Surg. 2005 Mar;31(3):371-374. (Pubitemid 43073002)
13. Moore RA, Edwards JE, Hopwood J, Hicks D. Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infect Dis. 2001;1:3. Epub 2001 Jun 5. Review. (Pubitemid 38750883)
14. Nouri K, O'Connell C, Rivas MP. Imiquimod for the treatment of Bowen's disease and invasive squamous cell carcinoma. J Drugs Dermatol. 2003 Dec;2(6):669-673.
15. Oster-Schmidt C. Two cases of squamous cell carcinoma treated with topical imiquimod 5%. J Eur Acad Dermatol Venereol. 2004 Jan;18(1):93-95. (Pubitemid 38159369)
16. Oster-Schmidt C, Dirschka T. Therapy of cutaneous cell carcinoma in two retirement home residents. J Dtsch Dermatol. 2005 Sep;3(9):705-708. (Pubitemid 43965324)
17. Persaud AN, Shamuelova E, Sherer D, Lou W, Singer G, Cervera C, Lamba S, Lebwohl MG. Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. J Am Acad Dermatol. 2002 Oct;47(4):553-556.
18. Sauder DN. Immunomodulatory and pharmacologic properties of imiquimod. J Am Acad Dermatol. 2000 Jul;43 (1 Pt 2):S6-11. Review.
19. Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, Ulrich C, Christophers E. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol. 2002 Nov;138(11):1498-1502. (Pubitemid 35315741)
20. Stockfleth E, Sterry W, Carey-Yard M, Bichel J. Multicentre, open-label study using imiquimod 5% cream in one or two 4-week courses of treatment for multiple actinic keratoses on the head. Br J Dermatol. 2007 Dec;157 Suppl 2: 41-46. (Pubitemid 350179629)
21. Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, Lee JH, Fox TL, Alomar A. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol. 2004 Oct;51(4): 547-555. (Pubitemid 39278073)
22. Urosevic M, Maier T, Benninghoff B, Slade H, Burg G, Dummer R. Mechanisms underlying imiquimod-induced regression of basal cell carcinoma in vivo. Arch Dermatol. 2003 Oct;139(10):1325-1332. (Pubitemid 37248283)
23. Wehrli P, Viard I, Bullani R, Tschopp J, French LE. Death receptors in cutaneous biology and disease. J Invest Dermatol. 2000 Aug;115(2):141-148. Review. (Pubitemid 30637180)